Chronic Kidney Disease Drugs Market – Global Forecast to 2025
- March, 2019
- Domain: Healthcare - Pharmaceuticals
- Get Free 10% Customization in this Report
[85 pages report] This market research report includes a detailed segmentation of the global chronic kidney disease drugs market by drug class (antihypertensives, antihyperlipidemics, erythropoiesis-stimulating agents (ESAs), diuretics, and others), by end-users (hospitals and specialty clinics), by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Chronic Kidney Disease Drugs Market
Infoholic’s market research report predicts that the “Global Chronic Kidney Disease Drugs Market” will grow at a CAGR of 4.1% during the forecast period. The market has witnessed flat growth in the past few years and is sustaining only due to the steady rise in the incidence of renal disorders leading to chronic kidney disease, increasing incidences of cardiovascular and metabolism-related disorders, and growing geriatric population globally.
The growing market trend continues and is one of the increasingly accepted markets in many countries worldwide. Chronic kidney disease drugs manufacturers are focusing on obtaining funds and collaborating with universities to enlarge their R&D capabilities. A majority of the revenue is generated from the leading players in the market with dominant sales from AbbVie, Amgen, GlaxoSmithKline, Roche, and AstraZeneca.
According to Infoholic Research analysis, North America accounted for the largest share of the global chronic kidney disease drugs market in 2018. The US dominates the market owing to the presence of a majority of the chronic kidney disease drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the large kidney disease patient population and increasing awareness about the disease.
By Drug Class:
- Erythropoiesis-stimulating agents (ESAs)
The antihypertensives segment occupied the largest share in 2018. Currently, KBP Biosciences and Medpace, Inc. are conducting Phase 2 randomized clinical trial on KBP-5074 for patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.
- Specialty Clinics
In 2018, hospitals accounted for the maximum share, followed by specialty clinics, due to the availability of technologically-advanced diagnostic equipment for the early diagnosis of the condition.
- North America
North America is dominant in the global chronic kidney disease drugs market, followed by Asia Pacific and Europe. The significant share of the North America market comes from the US due to the availability of good reimbursement policies.
Chronic Kidney Disease Drugs Market Research Competitive Analysis – The market is growing at a flat rate, with a single-digit CAGR during the forecast period. Various initiatives are taken by government establishments and market players to increase awareness among individuals. Campaigns are conducted globally to encourage people in adopting healthy lifestyles. Many countries are focusing on national programs to create disease awareness, prevention, and treatment options; for example, country-level national dialysis program, kidney disease education portals, launch of kidney-related disorder treatment funding initiatives, etc. Exhaustive pipeline for chronic kidney disease drugs is promising and is much required for future market growth. For example, ROXADUSTAT (HIF-PHI) by FibroGen is currently being studied in Phase-III clinical trials in the US, Europe, China, and Japan. Dapagliflozin by AstraZeneca is currently in phase III to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD).
- AbbVie Inc.
- Amgen Inc.
- GlaxoSmithKline plc
- Hoffmann-La Roche Ltd.
Key Competitive Facts
- Increasing CKD incidence, aging population, promising repayment or reimbursement plans in few nations, and enormous R&D activities for the CKD drug development are the major factors driving the market growth.
- Cell therapy produces better results in the earlier stages of kidney disease and has been shown to eliminate or reduce the need for regular dialysis.
- Research is being conducted to study the potential of miRNA as effective biomarkers and therapeutic targets for CKD treatments.
Benefits – The report provides complete details about the sub-segments of the chronic kidney diseases drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
- Understanding the potential market opportunity with precise market size and forecast data.
- A detailed market analysis focusing on the growth of chronic kidney diseases drugs
- Factors influencing the growth of the chronic kidney disease drugs
- In-depth competitive analysis of dominant and pure-play vendors.
- Prediction analysis of the chronic kidney diseases drugs market in both developed and developing regions.
- Key insights related to major segments of the chronic kidney diseases drugs
- Latest market trend analysis impacting the buying behavior of the consumers.
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
1.2.1 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.3 Industry Trends
3.4 Related Markets
3.4.1 Active Pharmaceutical Ingredients
3.4.2 Over-the-Counter Drugs
3.4.3 Diabetes Drugs
4 Market Outlook
4.1 Market Segmentation
4.2 Porter 5 (Five) Forces
5 Market Characteristics
5.1 Market Dynamics
220.127.116.11 High incidence of chronic kidney disease
18.104.22.168 Rise in the incidence of cardiovascular disorders and diabetes
22.214.171.124 Increase in the global geriatric population
126.96.36.199 Competition from biosimilars
188.8.131.52 Complex drug development process
184.108.40.206 Promising chronic kidney disease drug pipeline
220.127.116.11 Market expansion opportunities in emerging nations
18.104.22.168 Novel therapeutic approaches such as cell therapy
5.1.4 DRO – Impact Analysis
5.2 Key Stakeholders
6 Drug Class: Market Size and Analysis
6.4 Erythropoiesis-stimulating Agents (ESAs)
6.5 Diuretics Drugs
7 End-users: Market Size and Analysis
7.3 Specialty Clinics
8 Regions: Market Size and Analysis
8.2 North America
8.4 Asia Pacific
8.5 Rest of the World
9 Competitive Landscape
10 Vendors Profile
10.1 AbbVie Inc.
10.1.2 Geographic Presence
10.1.3 Business Focus
10.1.4 SWOT Analysis
10.1.5 Business Strategies
10.2 Amgen Inc.
10.2.2 Geographic Presence
10.2.3 Business Focus
10.2.4 SWOT Analysis
10.2.5 Business Strategies
10.3 GlaxoSmithKline plc
10.3.2 Geographic Presence
10.3.3 Business Focus
10.3.4 SWOT Analysis
10.3.5 Business Strategies
10.4 F. Hoffmann-La Roche Ltd.
10.4.2 Business Units
10.4.3 Geographic Revenue
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 Astra Zeneca PLC
10.5.2 Geographic Presence
10.5.3 Business Focus
10.5.4 SWOT Analysis
10.5.5 Business Strategies
11 Companies to Watch for
11.1 Pfizer Inc.
11.3 Teva Pharmaceutical Industries Ltd.
11.4 Johnson & Johnson
11.5 Keryx Biopharmaceuticals Inc.
11.6 FibroGen Inc.
TABLE 1 FDA APPROVED DRUGS FOR NEPHROLOGY 2015-2018 9
TABLE 2 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE, BY DRUG CLASS, 2018-2025 ($MILLION) 30
TABLE 3 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2018-2025 ($MILLION) 41
TABLE 4 ABBVIE INC.: OFFERINGS 51
TABLE 5 ABBVIE INC.: RECENT DEVELOPMENTS 51
TABLE 6 AMGEN INC.: OFFERINGS 56
TABLE 7 AMGEN INC.: RECENT DEVELOPMENTS 56
TABLE 8 GLAXOSMITHKLINE PLC: OFFERINGS 61
TABLE 9 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 61
TABLE 10 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 66
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 66
TABLE 12 ASTRAZENECA PLC: OFFERINGS 71
TABLE 13 ASTRAZENECA PLC: RECENT DEVELOPMENTS 72
TABLE 14 PFIZER INC.: SNAPSHOT 77
TABLE 15 MERCK KGAA: RECENT DEVELOPMENTS 77
TABLE 16 SANOFI: SNAPSHOT 78
TABLE 17 SANOFI: RECENT DEVELOPMENTS 78
TABLE 18 TEVA PHARMACEUTICAL INDUTRIES.: OVERVIEW 79
TABLE 19 TEVA PHARMACEUTICAL INDUTRIES: RECENT DEVELOPMENTS 79
TABLE 20 EDITAS MEDICINE: OVERVIEW 81
TABLE 21 EDITAS MEDICINE.: RECENT DEVELOPMENTS 81
TABLE 22 KERYX BIOPHARMACEUTICALS, INC: SNAPSHOT 81
TABLE 23 KERYX BIOPHARMACEUTICALS, INC: RECENT DEVELOPMENTS 82
TABLE 24 FIBROGEN INC.: OVERVIEW 82
TABLE 25 FIBROGEN INC.: RECENT DEVELOPMENTS 82
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.